Hyperinsulinemia and Hypovitaminosis D Among Overweight Adolescents



Ge B, Long K, Pancoast T, Tosh A Department of Child Health, University of Missouri School of Medicine



Background

In the past two decades, the prevalence of childhood obesity has doubled. Obesity, insulin resistance, and type 2 diabetes mellitus have been shown to be interrelated. Hypovitaminosis D has also been shown to be more prevalent in overweight patients. Because current studies regarding insulin resistance and hypovitaminosis D have focused on the adult population, we have chosen to examine the adolescent population in this study.

Purpose

To evaluate associations between hyperinsulinemia, vitamin D levels, and obesity in an adolescent cohort, as well as ensure the safety and efficacy vitamin D2, 50,000 IU weekly therapy.

Methods

Subjects aged 10-18 years old attending the Adolescent Obesity and Diabetes Clinic were recruited to participate in a cross-sectional study. Body Mass Index (BMI), fasting serum insulin, preand post-therapy 25-hydroxyvitamin D and calcium levels were examined. Low serum 25-hydroxyvitamin D (hypovitaminosis D) was categorized as normal (≥30 ng/mL), insufficient (≥20 ng/mL), and deficient (<20 ng/mL). BMI percentiles were classified as overweight (>85%) and obese (>95%). Patients with a fasting serum insulin level >20 mc unit/mL were considered to have hyperinsulinemia. Spearman's rank correlation coefficients were computed and statistical significance was established (p <0.05).

Results

The study included 297 adolescents, with mean age at first visit of 13.6 years. Among 195 subjects for whom initial fasting insulin levels were obtained, 59% had hyperinsulinemia. Mean 25-hydroxyvitamin D among 168 subjects was 23.0 ng/mL (SD 9.2), 70 (42%) were vitamin D insufficient, and 68 (40%) were vitamin D deficient (Table 1). Prior to treatment, mean serum 25OH vitamin D level was 14.52 ng/mL (SD 2.73) and calcium level was 9.58 mg/dL (SD 0.45). After 8 weeks of high dose therapy, mean 25OH vitamin D level was 25.74 ng/mL (SD 8.56) and calcium level was 9.44 mg/dL (SD 0.49) (Figure 1). Increased BMI was associated with increased fasting insulin (r=.38, p=0.0035) and age (r=0.39, p=<0.0001). Of the 227 subjects with multiple BMIs reported over time, 92 (41%) demonstrated BMI reduction.

Table 1.
Comparison of
Mean 25Hydroxyvitamin
D Levels

250H Vitamin D classification	N	%
Normal (>30 ng/mL)	30	18%
Insufficient (20-30 ng/mL)	70	42%
Deficient (<20 ng/mL)	68	40%
Total	168	100%

Figure 1: Effect
of High Dose
Therapy on
Serum 25Hydroxyvitamin
D and Calcium
Levels

30 25 20 15 10 5	Pre-High Dose	Post-High D	 Serum 25Ol Vitamin D (ng/mL) Serum Ca (mg/dL) 	
	Pre-High Dose Post-High Dose Therapy Therapy			

Interpretation and Future Plans

For patients who received high dose therapy, the improvement in the 25OH vitamin D level was significant (p<0.001). There was no observed increase in calcium levels, so the high dose vitamin D2 therapy was considered safe. A statistically significant association was found between BMI and hyperinsulinemia. findings suggest that obesity may be a risk factor for hyperinsulinemia and hypovitaminosis D. Data suggests that weight stabilization and weight loss are reasonable and realistic goals in the context of a medical weight disorders clinic. A limitation of this study is the small sample size. Further investigation should be performed, including determining the effect of high dose vitamin D2 therapy on BMI in adolescents.

References

Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.

Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.

Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713.